Lv4
490 积分 2023-11-21 加入
Increasing the efficacy of CD20 antibody therapy through the engineering of a new type II anti-CD20 antibody with enhanced direct and immune effector cell–mediated B-cell cytotoxicity
4天前
已关闭
BCMA-Targeted T-Cell–Engager Therapy for Autoimmune Disease
7天前
已完结
Achievable but elusive: LLDAS and DORIS remission in clinical trials of belimumab
7天前
已完结
Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors
1个月前
已完结
The BAFFling effects of rituximab in lupus: danger ahead?
1个月前
已完结
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
2个月前
已完结
Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus
2个月前
已完结
A 5-Year Follow-up of Rituximab Treatment in Patients With Neuromyelitis Optica Spectrum Disorder
3个月前
已完结
ACTRIIA-Fc rebalances activin/GDF versus BMP signaling in pulmonary hypertension
4个月前
已完结
[Chinese expert consensus on clinical testing standards of PD-L1 expression for non-small cell lung cancer (2023 version)]
5个月前
已完结
皖公网安备34019202002308
